Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30717792 | 1.00 | CSNK2A1 (0.50) | CSNK2A1RORCKMT2AMEN1TSHR | |
| SCHEMBL2419182 | 0.93 | CSNK2A1 (0.59) | CSNK2A1RORCKMT2ALMNANPSR1 | |
| SCHEMBL16595460 | 0.93 | CSNK2A1 (0.55) | CSNK2A1RORCKMT2ALMNANPSR1 | |
| SCHEMBL739389 | 0.88 | SYK (0.48) | CSNK2A1RORCKMT2ALMNAKDM4E | |
| SCHEMBL2254495 | 0.86 | RORC (0.50) | RORCKMT2AMEN1TSHRLMNA | |
| SCHEMBL16695295 | 0.85 | KDM4E (0.50) | RORCKDM4E | |
| SCHEMBL265784 | 0.85 | SLC6A4 (0.43) | RORCSLC6A4HTR6KMO | |
| SCHEMBL16695141 | 0.84 | KMO (0.46) | CSNK2A1KMT2AMEN1TSHRLMNA | |
| SCHEMBL2254053 | 0.83 | RORC (0.53) | RORCKMT2AMEN1TSHRLMNA | |
| SCHEMBL2254055 | 0.83 | RORC (0.53) | RORCKMT2AMEN1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130583-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117126152-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117069712-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069713-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117024420-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070197640-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197640-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007056056-A2 | MITOTIC KINESIN INHIBITORS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CSNK2A1 4262/4885RORC 4335/4885KMT2A 4011/4885 |
| US-20070197640-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CSNK2A1 401/4885RORC 1743/4885KMT2A 1501/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CSNK2A1 4450/4885RORC 4392/4885KMT2A 3699/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | CSNK2A1 1151/4885RORC 2537/4885KMT2A 1040/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CSNK2A1 401/4885RORC 1743/4885KMT2A 1501/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CSNK2A1 4262/4885RORC 4335/4885KMT2A 4011/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CSNK2A1 401/4885RORC 1743/4885KMT2A 1501/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CSNK2A1 401/4885RORC 1743/4885KMT2A 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.